2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2020
Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery
Togioka BM, Yanez D, Aziz MF, Higgins JR, Tekkali P, Treggiari MM. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. British Journal Of Anaesthesia 2020, 124: 553-561. PMID: 32139135, DOI: 10.1016/j.bja.2020.01.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCholinesterase InhibitorsDelayed Emergence from AnesthesiaDouble-Blind MethodFemaleHumansIntraoperative PeriodLung DiseasesMaleNeostigmineNeuromuscular BlockadeNeuromuscular JunctionNeuromuscular Nondepolarizing AgentsPatient ReadmissionPostoperative ComplicationsRocuroniumSugammadexConceptsPostoperative pulmonary complicationsResidual neuromuscular blockPulmonary complicationsDay hospital readmissionNeuromuscular blockPrimary endpointHospital readmissionDay hospital readmission rateOlder adultsHospital readmission ratesPhase 1 recoveryRocuronium reversalNeostigmine groupSecondary endpointsSugammadex groupReadmission ratesResidual paralysisSurgical closureSugammadexComplicationsNeostigmineLarger studySurgeryIncidenceEndpoint
2019
Education Program Regarding Labor Epidurals Increases Utilization by Hispanic Medicaid Beneficiaries: A Randomized Controlled Trial.
Togioka BM, Seligman KM, Werntz MK, Yanez ND, Noles LM, Treggiari MM. Education Program Regarding Labor Epidurals Increases Utilization by Hispanic Medicaid Beneficiaries: A Randomized Controlled Trial. Anesthesiology 2019, 131: 840-849. PMID: 31299658, DOI: 10.1097/aln.0000000000002868.Peer-Reviewed Original ResearchConceptsRoutine care groupEpidural labor analgesiaNon-Hispanic womenNon-Hispanic cohortsRoutine careHispanic womenEpidural analgesiaLabor analgesiaEpidural useCare groupLabor epiduralsMedicaid beneficiariesNon-Hispanic ethnicityPrimary endpointSecondary endpointsAdverse eventsControlled TrialsObstetric providersEducational programsIntervention groupAcademic hospitalIndependent cohortAnalgesiaPerson counselingHealthcare disparities
2018
Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine
Thilen SR, Ng IC, Cain KC, Treggiari MM, Bhananker SM. Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine. British Journal Of Anaesthesia 2018, 121: 367-377. PMID: 30032875, DOI: 10.1016/j.bja.2018.03.029.Peer-Reviewed Original ResearchConceptsPostoperative residual neuromuscular blockResidual neuromuscular blockNeuromuscular blockTracheal extubationNeostigmine reversalRocuronium neuromuscular blockIdeal body weightConfidence intervalsNeostigmine administrationRocuronium administrationSecondary endpointsAppropriate dosingAbdominal surgeryFemale sexDose reductionExtubationBody weightControl groupPatientsIncidenceSurgical requirementsSignificant differencesNeostigmineAdministrationSubjective monitoring
2016
Comparison of enteral ethanol and benzodiazepines for alcohol withdrawal in neurocritical care patients
Gipson G, Tran K, Hoang C, Treggiari M. Comparison of enteral ethanol and benzodiazepines for alcohol withdrawal in neurocritical care patients. Journal Of Clinical Neuroscience 2016, 31: 88-91. PMID: 27262870, DOI: 10.1016/j.jocn.2016.02.028.Peer-Reviewed Original ResearchConceptsEnteral ethanolCIWA scoreAlcohol withdrawalEthanol groupIntensive care unit lengthClinical Institute Withdrawal AssessmentAlcohol withdrawal managementRetrospective chart reviewNeurocritical care patientsGlasgow Coma ScaleLength of stayUse of benzodiazepinesLevel of comaAlcohol scale scoresPrimary endpointSecondary endpointsChart reviewClinical characteristicsFirst medicationCare patientsComa ScaleOral intakeEthanol withdrawalWithdrawal AssessmentNeurocritical care
2011
Open-Label Randomized Trial of the Safety and Efficacy of a Single Dose Conivaptan to Raise Serum Sodium in Patients with Traumatic Brain Injury
Galton C, Deem S, Yanez ND, Souter M, Chesnut R, Dagal A, Treggiari M. Open-Label Randomized Trial of the Safety and Efficacy of a Single Dose Conivaptan to Raise Serum Sodium in Patients with Traumatic Brain Injury. Neurocritical Care 2011, 14: 354-360. PMID: 21409494, DOI: 10.1007/s12028-011-9525-8.Peer-Reviewed Original ResearchConceptsTraumatic brain injurySevere traumatic brain injuryUsual care groupIntracranial pressureSerum sodiumAdverse eventsUrine outputCare groupSodium loadBrain injuryDrug-related serious adverse eventsEffects of conivaptanLabel Randomized TrialNon-hyponatremic patientsSerum sodium increaseSerious adverse eventsTreatment of hyponatremiaSodium increasesMethodsOpen-labelNormonatremic patientsPrimary endpointResultsTen patientsSecondary endpointsUsual careMean sodium